

30 March 2015

PRE-QUOTATION DISCLOSURE NOTICE

The following information is required to be given to ASX Limited (**ASX**) for release to the market in connection with the commencement of official quotation in the fully paid ordinary shares (**Shares**) in Genetic Signatures Limited (ACN 095 913 205) (**Genetic Signatures**) (ASX: GSS).

Unless otherwise defined in this notice, capitalised terms used in this notice have the meanings given to them in the prospectus lodged by Genetic Signatures with the Australian Securities and Investments Commission (**ASIC**) on 7 November 2014 (**Prospectus**), as supplemented by the supplementary prospectus lodged with ASIC on 6 February 2015 (**Supplementary Prospectus**).

1. Close of Offer and issue of Shares

Genetic Signatures confirms that the Offer has closed and that:

- 18,750,000 Shares have been issued to applicants under the Prospectus (at an issue price of \$0.40 per Share); and
- 4,675,000 Shares have been issued under the Employee Share Ownership Plan.

Genetic Signatures has received cleared funds for the complete amount of the issue price of every Share issued to applicants under the Prospectus. No funds were payable to Genetic Signatures for the Shares issued under the Employee Share Ownership Plan.

On the basis of Genetic Signatures' share price of \$0.40, under the Prospectus, and a shareholder register with 565 shareholders each with a shareholding of \$2,000 or greater, Genetic Signatures is satisfied that it has an appropriate level of shareholder spread for the purposes of ASX Listing Rule 1.1 condition 7.

The CHESS holding notices and issuer sponsored holding statements were despatched to successful applicants under the Offer on 26 March 2015. All refund monies were despatched on 30 March 2015.

The CHESS holding notices and issuer sponsored holding statements were despatched to persons issued Shares under the Employee Share Ownership Plan on 27 March 2015.

2. Capital structure and escrow

Genetic Signatures currently has 72,938,990 Shares on issue.

A total of 2,872,355 Shares held by Shareholders are subject to mandatory escrow arrangements of a 24 month period from the date on which quotation of the Shares on ASX commences.

In addition, voluntary escrow arrangements will apply in respect of a further 34,236,690 Shares held by one of the Shareholders, Asia Union Investments Pty Ltd. 18,434,065 of the Shares under voluntary escrow arrangements will be released from escrow 12 months after the date on which quotation of the Shares on ASX commences and the remaining balance of 15,802,625 Shares held under voluntary escrow arrangements will be released from escrow 24 months after that date.

In addition, the 4,675,000 shares issued under the Employee Share Ownership Plan (see section 3 below) will be subject to trading restrictions. These Shares will vest and become clear of trading restrictions progressively over a 48 month period.

For further detail in relation to the voluntary escrow arrangements entered into by Genetic Signatures with certain of its Shareholders and the trading restrictions on Shares issued under the Employee Share Ownership Plan, please see Sections 1, 9.4, 9.8(b) and 9.8(d)(1) of the Prospectus and Sections 4.3(b) and 4.7 of the Supplementary Prospectus.

3. Employee share ownership plan

Genetic Signatures has issued 4,675,000 Shares to employees under Genetic Signatures' Employee Share Ownership Plan.

The Employee Shares were issued on 27 March 2015. A copy of the Genetic Signatures' Employee Share Ownership Plan at the date of this notice is released as part of Genetic Signatures' Pre-Quotation Disclosure. For further details of the Employee Share Ownership Plan please also see sections 9.8(d)(i) of the Prospectus.

4. Corporate governance


A statement disclosing the extent to which Genetic Signatures will follow, as at the date of admission to the official list of ASX, the recommendations set by the ASX Corporate Governance Council is released as part of Genetic Signatures' Pre-Quotation Disclosure.

A copy of Genetic Signatures' share trading policy at the date of this notice is also released as part of Genetic Signatures' Pre-Quotation Disclosure.

5. Working capital sufficiency

The Directors reaffirm the statement made in the Prospectus that, in the opinion of the Directors, on completion of the Offer Genetic Signatures will have sufficient working capital to carry out its objections as stated in the Prospectus (as supplemented by the Supplementary Prospectus).

For further detail on any of the matters referred to in this notice, please see the Prospectus, available on Genetic Signatures' or ASX's website or contact your professional adviser.



Rob Birrell
Chief Financial Officer
Genetic Signatures Limited

+61 2 98707580